{"schema_version":"secwatch.filing_event.v1","accession":"0000914475-26-000025","form_type":"8-K","ticker":"NBIX","cik":"0000914475","company_name":"NEUROCRINE BIOSCIENCES INC","filed_at":"2026-05-05T23:59:59+00:00","discovered_at":"2026-05-14T18:02:33.928748+00:00","generated_at":"2026-05-14T23:48:02.472902+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.9,"calibrated_materiality_score":0.9,"confidence":"high","headline":"Neurocrine Biosciences reports Q1 2026 sales $811M (up 44%); agrees to acquire Soleno Therapeutics for $2.9B","bullets":["Net product sales of $811.0M in Q1 2026, a 44% increase year-over-year, led by INGREZZA ($656.9M) and CRENESSITY ($153.3M).","Definitive agreement to acquire Soleno Therapeutics for $53.00 per share ($2.9B equity value), expected to close in Q2 2026.","Initiated Phase 2 study of NBI-1117570 (dual M1/M4 agonist) for schizophrenia and Phase 1 study of NBIP-’2118 (CRF2 agonist) for obesity.","Reaffirmed full-year 2026 INGREZZA net sales guidance of $2.7-$2.8 billion and total cash of $2.65 billion at March 31, 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0000914475-26-000025","json":"https://secwatch.observer/filing/0000914475-26-000025.json","markdown":"https://secwatch.observer/filing/0000914475-26-000025.md","text":"https://secwatch.observer/filing/0000914475-26-000025.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/914475/000091447526000025/0000914475-26-000025-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/914475/000091447526000025/nbix-20260505.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud","generated_at":"2026-05-14T23:48:02.472902+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"4b9fbeddc1d92f93c69adfed93426232156f90a9","claim":"NEUROCRINE BIOSCIENCES INC reported first quarter ended March 31, 2026 results: revenue 814.5 million dollars, net income 197.9 million dollars, EPS 1.91 dollars per share. Guidance reaffirmed.","evidence_excerpt":"Neurocrine Biosciences Reports First-Quarter 2026 Financial Results Total First-Quarter 2026 Net Product Sales of $811.0 Million, An Increase of 44% Year-Over-Year Announced Definitive Agreement to Acquire Soleno Therapeutics, Including VYKAT TM XR (diazoxide choline) for the Treatment of Hyperphagia in Prader-Willi Syndrome Expected to Close in Q2 2026 Initiated Phase 2 Clinical Study of NBI-1117570, a Dual M1 / M4 Selective Agonist, in Adults with Schizophrenia Reaffirmed 2026 Full-Year INGREZZA ® (valbenazine) Net Sales Guidance of $2.7 - $2.8 Billion SAN DIEGO , May 5, 2026 – Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced its financial results for the first quarter ended March 31, 2026.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/914475/000091447526000025/0000914475-26-000025-index.htm","confidence":0.99,"family_label":"Earnings Releases","details":[{"label":"Period","value":"first quarter ended March 31, 2026"},{"label":"Revenue","value":"814.5 million dollars"},{"label":"Net income","value":"197.9 million dollars"},{"label":"EPS","value":"1.91 dollars per share"},{"label":"Guidance","value":"reaffirmed"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}